The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden administration that would have allowed Medicare and Medicaid ...

The previous administration attempted to have Medicare Part D and Medicaid cover anti-obesity drugs under the Contract Year 2026 MA and Part D rule, which would have substantially increased access ...

High-demand obesity treatments will not be covered under the federal government’s Medicare program, it was announced Friday. The Centers for Medicare and Medicaid Services said late Friday that ...

The Centers for Medicare and Medicaid Services did ... in a statement that it may consider future policy options for anti-obesity medications “pending further review of both the potential ...

The Trump administration said Friday that Medicare and Medicaid won’t expand coverage of popular anti-obesity drugs, rejecting a proposal issued late last year by the Biden administration.

The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate.

South Carolina Medicaid approved GLP-1s to treat obesity, placing it among the few state programs covering the drugs. But access remains limited.

House of Delegates today passed the Endocrine Society's resolution to improve access to anti-obesity medications.

The bad news is that Medicaid does not cover anti-obesity medications in New York, putting life-changing treatment out of reach for those who need it most. Fourteen states and counting have begun ...